Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

David E. Avigan, M.D.

Co-Author

This page shows the publications co-authored by David Avigan and Maxwell Coll.
Connection Strength

0.865
  1. MUC1-C drives myeloid leukaemogenesis and resistance to treatment by a survivin-mediated mechanism. J Cell Mol Med. 2018 Aug; 22(8):3887-3898.
    View in: PubMed
    Score: 0.190
  2. MUC1-mediated induction of myeloid-derived suppressor cells in patients with acute myeloid leukemia. Blood. 2017 Mar 30; 129(13):1791-1801.
    View in: PubMed
    Score: 0.174
  3. Bone marrow stroma protects myeloma cells from cytotoxic damage via induction of the oncoprotein MUC1. Br J Haematol. 2017 03; 176(6):929-938.
    View in: PubMed
    Score: 0.174
  4. Individualized vaccination of AML patients in remission is associated with induction of antileukemia immunity and prolonged remissions. Sci Transl Med. 2016 12 07; 8(368):368ra171.
    View in: PubMed
    Score: 0.172
  5. Mucin 1 is a potential therapeutic target in cutaneous T-cell lymphoma. Blood. 2015 Jul 16; 126(3):354-62.
    View in: PubMed
    Score: 0.155
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.